X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: BAN2401
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2021
Details:
The presentations will include the latest data of the investigational anti-amyloid beta (Aβ) protofibril selective antibody lecanemab (BAN2401) for which the FDA has granted Breakthrough Therapy designation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Isoflurane
Therapeutic Area: Neurology Product Name: Sedaconda
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2021
Details:
The topline results, announced in July 2020, showed that the study reached its primary goal; to show that Sedaconda administered via AnaConDa is an effective sedation method for ventilated ICU patients, comparable to propofol.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
